Work

Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.tps206

Authors: Michael J. Morris, A. Oliver Sartor, Jeffrey Y.C. Wong, Steven I Max, Hong Xie, Mike Russell, Chaitanya R Divgi, Daniel Patricia, Anjali Narayan Avadhani, Luke T. Nordquist

Institutions: Memorial Sloan Kettering Cancer Center, Tulane University, City Of Hope National Medical Center, Urology Cancer Center and GU Research Network

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4212855381

Cites:

Cited by: 5

Related to: 10